<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Rights</title>
	<atom:link href="http://www.tapanray.in/tag/rights/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Reverberations Around The Proposed New IPR Policy Of India</title>
		<link>http://www.tapanray.in/reverberations-around-the-proposed-new-ipr-policy-of-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=reverberations-around-the-proposed-new-ipr-policy-of-india</link>
		<comments>http://www.tapanray.in/reverberations-around-the-proposed-new-ipr-policy-of-india/#comments</comments>
		<pubDate>Mon, 16 Feb 2015 00:00:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[Arjun Jayadev]]></category>
		<category><![CDATA[Barack]]></category>
		<category><![CDATA[Dean Baker]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Joseph E. Stiglitz]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[MSF]]></category>
		<category><![CDATA[Narendra]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[Obama]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[President]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Rights]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[World Trade Organization (WTO)]]></category>
		<category><![CDATA[‘Project Syndicate’]]></category>
		<category><![CDATA[‘The World Opinion Page’]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6381</guid>
		<description><![CDATA[“If the Obama administration succeeds in forcing India to strengthen its patent laws, the change would harm not only India and other developing countries; it would also enshrine a grossly corrupt and inefficient patent system in the US, in which &#8230; <a href="http://www.tapanray.in/reverberations-around-the-proposed-new-ipr-policy-of-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/reverberations-around-the-proposed-new-ipr-policy-of-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New “National IPR Policy” of India – A Pharma Perspective</title>
		<link>http://www.tapanray.in/new-national-ipr-policy-of-india-a-pharma-perspective/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=new-national-ipr-policy-of-india-a-pharma-perspective</link>
		<comments>http://www.tapanray.in/new-national-ipr-policy-of-india-a-pharma-perspective/#comments</comments>
		<pubDate>Mon, 19 Jan 2015 00:00:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[301]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Congress]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Hatch]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Justice]]></category>
		<category><![CDATA[lawmakers]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[OCR]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[Orrin]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[perspective]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Prabha]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Rights]]></category>
		<category><![CDATA[Senator]]></category>
		<category><![CDATA[sofosbuvir]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Special]]></category>
		<category><![CDATA[Sridevan]]></category>
		<category><![CDATA[Tank]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Think]]></category>
		<category><![CDATA[TPF]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USTR]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6330</guid>
		<description><![CDATA[Whether under pressure or not, is hardly of any relevance now. What is relevant today is the fact that the new Indian Government, almost in a record time of just around two months, has been able to release a high &#8230; <a href="http://www.tapanray.in/new-national-ipr-policy-of-india-a-pharma-perspective/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/new-national-ipr-policy-of-india-a-pharma-perspective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>“India is The Biggest Battlefield for Intellectual Property Rights”</title>
		<link>http://www.tapanray.in/india-is-the-biggest-battlefield-for-intellectual-property-rights/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-is-the-biggest-battlefield-for-intellectual-property-rights</link>
		<comments>http://www.tapanray.in/india-is-the-biggest-battlefield-for-intellectual-property-rights/#comments</comments>
		<pubDate>Wed, 05 Feb 2014 05:59:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[301]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[battlefield]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[Biggest]]></category>
		<category><![CDATA[body]]></category>
		<category><![CDATA[Chamber]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Commerce]]></category>
		<category><![CDATA[Consilium]]></category>
		<category><![CDATA[dispute]]></category>
		<category><![CDATA[GIPC]]></category>
		<category><![CDATA[Hatch]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Israel]]></category>
		<category><![CDATA[Orrin]]></category>
		<category><![CDATA[PAE]]></category>
		<category><![CDATA[patentability]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Pugatch]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[restoration]]></category>
		<category><![CDATA[Rights]]></category>
		<category><![CDATA[Senator]]></category>
		<category><![CDATA[settlement]]></category>
		<category><![CDATA[South]]></category>
		<category><![CDATA[Special]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[term]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4965</guid>
		<description><![CDATA[The US Senator Orrin Hatch reportedly made the above comment while introducing the 2014 report on ‘International Intellectual Property (IP) Index’, prepared by an Israel based consultancy firm &#8211; Pugatch Consilium for the Global Intellectual Property Centre (GIPC) of the &#8230; <a href="http://www.tapanray.in/india-is-the-biggest-battlefield-for-intellectual-property-rights/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-is-the-biggest-battlefield-for-intellectual-property-rights/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Counterfeit Drugs and ACTA: Should the global menace related to &#8216;Public Health and Safety&#8217; be mixed-up with Intellectual Property Rights?</title>
		<link>http://www.tapanray.in/counterfeit-drugs-and-acta-should-the-global-menace-related-to-public-health-and-safety-be-mixed-up-with-intellectual-property-rights/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=counterfeit-drugs-and-acta-should-the-global-menace-related-to-public-health-and-safety-be-mixed-up-with-intellectual-property-rights</link>
		<comments>http://www.tapanray.in/counterfeit-drugs-and-acta-should-the-global-menace-related-to-public-health-and-safety-be-mixed-up-with-intellectual-property-rights/#comments</comments>
		<pubDate>Mon, 02 Jul 2012 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[ACTA]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[menace]]></category>
		<category><![CDATA[mixed-up]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[related]]></category>
		<category><![CDATA[Rights]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Should]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=72</guid>
		<description><![CDATA[Here in this article, I am talking about drugs or medicines, which you may ultimately land up into buying, quite innocently though, against your doctor’s prescriptions, without having an inkling that these drugs can push you into serious health hazards, &#8230; <a href="http://www.tapanray.in/counterfeit-drugs-and-acta-should-the-global-menace-related-to-public-health-and-safety-be-mixed-up-with-intellectual-property-rights/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/counterfeit-drugs-and-acta-should-the-global-menace-related-to-public-health-and-safety-be-mixed-up-with-intellectual-property-rights/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
